Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Serologic evidence of chronic hepatitis C infection by anti-HCV antibody test
Received peginterferon alfa-2a for at least 12 weeks and either did not reach a 2-log drop in HCV RNA after 12 weeks of treatment, did not reach an undetectable HCV RNA after 24 weeks of treatment, or reached undetectable HCV RNA that was detectable again at the end of 48 weeks of treatment
Detectable serum HCV RNA at Screening
Serologic evidence of HIV infection by HIV RNA detection
CD4 cell count greater than or equal to (\>/=) 100 cells/mcL during therapy with peginterferon alfa-2a plus ribavirin for at least 12 weeks
Stable HIV status and, if on antiretroviral therapy, a stable regimen for at least 6 weeks prior to Baseline
Compensated liver disease
No evidence of hepatocellular carcinoma
You may not be if
Pregnant or breastfeeding
Antineoplastic or immunomodulatory treatment within 6 months prior to first dose
Any investigational drug within 6 weeks prior to first dose
Positive for hepatitis A immunoglobulin M antibody
Severe neutropenia or thrombocytopenia at Screening while still on therapy with peginterferon alfa-2a plus ribavirin
Severe psychiatric or neurologic comorbidity
History of any significant medical conditions, such as immune disorders or disease of the major organ systems
